Assessment of controversial pediatric asthma management options using GRADE

Pediatrics

Volumn 130, Issue 3, 2012, Pages

  Boluyt, Nicole ^a   Rottier, Bart L ^b   De Jongste, Johan C ^c   Riemsma, Rob ^d   Vrijlandt, Elianne J L E ^b   Brand, Paul L P ^e  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^e ISALA HOSPITAL   (Netherlands)

Author keywords

Asthma; Bronchodilator agents; Child; Drug therapy; Evidence based medicine; Glucocorticoids; Guidelines; Leukotriene antagonists

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; DESISOBUTYRYLCICLESONIDE; DRUG METABOLITE; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; TETRACOSACTIDE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; AEROSOL; ARTICLE; ASTHMA; CHILD; CLINICAL PRACTICE; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GRADING OF RECOMMENDATIONS ASSESSMENT, DEVELOPMENT AND EVALUATION; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; PARTICLE SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RATING SCALE; RESPIRATORY TRACT INFLAMMATION; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL RESPIRATORY TRACT INFECTION; WHEEZING;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC;

EID: 84865727177     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3559     Document Type: Article

References (60)

1. Global strategy for asthma management and prevention (revised 2008): Global Initiative for Asthma (GINA). Available at: www.ginasthma.com. Accessed August 2011
2. British guidelines on the management of asthma. 2011. Available at: www.brit-thoracic.org.uk. Accessed August 2011
3. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. 2007. Available at: www.nhlbi.nih.gov/ guidelines/asthma/asthsumm.pdf. Accessed August 2011
4. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490
5. Atkins D, Eccles M, Flottorp S, et al; GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38
6. Schünemann HJ, Best D, Vist G, Oxman AD; GRADE Working Group. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677-680
7. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926
8. Schünemann HJ, Jaeschke R, Cook DJ, et al; ATS Documents Development and Implementation Committee. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174(5):605-614
9. Asthma in children. Guidelines developed by the Dutch Respiratory Society Group. Utrecht, the Netherlands: Dutch Respiratory Society Group; 2007
10. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0 (updated September 2008). The Cochrane Collaboration, 2008. Available at: www.cochrane-handbook.org. Accessed August 2011
11. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380-382
12. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504
13. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstätter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol. 2006;41(10):954-961
14. Pedersen S, Engelstätter R, Weber HJ, et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulm Pharmacol Ther. 2009;22(3):214-220
15. Robroeks CM, van de Kant KD, van Vliet D, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol . 2008;100(6):601-607
16. van Aalderen WM, Price D, De Baets FM, Price J. Beclometasone dipropionate extra-fine aerosol versus fluticasone propionate in children with asthma. Respir Med. 2007;101(7):1585-1593
17. Vermeulen JH, Gyurkovits K, Rauer H, Engelstätter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med. 2007;101(10):2182-2191
18. von Berg A, Engelstätter R, Minic P, et al; von BA. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol. 2007;18(5):391-400
19. James Lind Alliance. Research Priorities in Asthma (description of a workshop to set priorities for treatment uncertainty research in Asthma, March 2007). Available at: www. lindalliance.org/asthma-working-partnership.asp. Accessed August 2011
20. Zöllner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (part 2) - the risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol. 2007;18(6):469-474
21. Crowley S, Hindmarsh PC, Holownia P, Honour JW, Brook CG. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol. 1991;130(3):475-479
22. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941-955
23. Zöllner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids: part 1. Which test should be used [review]. ? Pediatr Allergy Immunol. 2007;18(5):401-409
24. Skoner DP, Maspero J, Banerji D; Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008;121(1). Available at: www.pediatrics.org/cgi/content/full/121/1/e1
25. Chapman KR. Safer inhaled corticosteroid therapy for asthma. Pediatrics. 2008;121(1):179-180
26. Malozowski S. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics. 2008;122(1):213
27. Brand PL, Baraldi E, Bisgaard H, et al. De finition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J. 2008;32(4):1096-1110
28. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ; The Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332(3):133-138
29. Bacharier LB, Phillips BR, Zeiger RS, et al CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127-1135, e8
30. Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol . 2007;120(5):1043-1050
31. Schultz A, Devadason SG, Savenije OE, Sly PD, Le Souëf PN, Brand PL. The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr. 2010;99(1):56-60
32. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with metaanalysis. Pediatrics. 2009;123(3). Available at: www.pediatrics.org/ cgi/content/full/123/3/e519
33. Schultz A, Brand PL. Episodic viral wheeze and multiple trigger wheeze in preschool children: a useful distinction for clinicians? Paediatr Respir Rev. 2011;12(3):160-164
34. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667-672
35. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 2010;95(5):365-370
36. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone. Arch Dis Child. 2001;85(2):143-148
37. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol. 2001;108(4):540-546
38. Teper AM, Kofman CD, Szulman GA, Vidaurreta SM, Maffey AF. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med. 2005;171(6):587-590
39. Brand PL. Inhaled corticosteroids reduce growth. Or do they? Eur Respir J. 2001;17(2):287-294
40. Lemanske RF Jr, Mauger DT, Sorkness CA, et al Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362(11):975-985
41. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2009; (3):CD007949
42. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, et al; COMBO Study Group. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med. 2010;182(10):1221-1227
43. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130(6):1733-1743
44. Heuck C, Heickendorff L, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child. 2000;83(4):334-339
45. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF; The Dutch Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med. 1998;158(1):213-219
46. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol. 2009;20(8):763-771
47. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Sträter C, Steinkamp G; VIAPAED Study Group. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol. 2009;44(11):1132-1142
48. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362(13):1169-1171
49. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics. 2011;128(5). Available at: www.pediatrics.org/cgi/content/full/128/5/e1147
50. Adams N, Lasserson TJ, Cates CJ, et al. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. 2007;2004:CD002310
51. Eijkemans M, Otten BJ, Yntema JB. [Adrenal cortex insufficiency in children due to inhaled corticosteroids]. Ned Tijdschr Geneeskd. 2011;155:A2862
52. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002;87(6):457-461
53. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-415
54. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395-400
55. Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99
56. Sinha IP, Williamson PR, Smyth RL. Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. PLoS ONE. 2009;4(7):e6276
57. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394
58. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037-2040
59. Cuello García CA, Pacheco Alvarado KP, Pérez Gaxiola G. Grading recommendations in clinical practice guidelines: randomised experimental evaluation of four different systems. Arch Dis Child. 2011;96(8):723-728
60. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011;364(26):2473-2475